Paper40238917
Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity.
Trepka KR and 18 others. Sci Transl Med, 2025. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Papers, record 40238917. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40238917
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Colorectal Neoplasms | Major topic |
| Fluorouracil | Major topic |
| Operon | Major topic |
| Pyrimidines | Major topic |
| Animals | |
| Female | |
| Humans | |
| Male | |
| Mice | |
| Gastrointestinal Microbiome | |
| RNA, Ribosomal, 16S |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K08 HL165106 | NHLBI NIH HHS | United States | K08HL165106 | PubMed | NIH RePORTER |
| R01 CA255116 | NCI NIH HHS | United States | R01CA255116 | PubMed and NIH | NIH RePORTER |
| T32 AI060537 | NIAID NIH HHS | United States | T32AI060537 | PubMed | NIH RePORTER |
| R01 DK114034 | NIDDK NIH HHS | United States | R01DK114034 | PubMed and NIH | NIH RePORTER |
| F30 CA257378 | NCI NIH HHS | United States | F30CA257378 | PubMed and NIH | NIH RePORTER |
| R01 HL122593 | NHLBI NIH HHS | United States | R01HL122593 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04054908 | Gut Microbiome in Colorectal Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 38895199 | Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity. | https://conductscience.org/library/papers/38895199 |
Source PubMed
References79
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27214047 | DADA2: High-resolution sample inference from Illumina amplicon data. | Nat Methods | 2016 | https://conductscience.org/library/papers/27214047 | PubMed |
| 2 | 37602831 | Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade. | Cancer Res | 2023 | https://conductscience.org/library/papers/37602831 | PubMed |
| 3 | 35228751 | Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. | Nat Med | 2022 | https://conductscience.org/library/papers/35228751 | PubMed |
| 4 | 21414208 | pROC: an open-source package for R and S+ to analyze and compare ROC curves. | BMC Bioinformatics | 2011 | https://conductscience.org/library/papers/21414208 | PubMed |
| 5 | 10555122 | A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. | Invest New Drugs | 1999 | https://conductscience.org/library/papers/10555122 | PubMed |
| 6 | 24167597 | Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. | PLoS One | 2013 | https://conductscience.org/library/papers/24167597 | PubMed |
| 7 | 33805100 | An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33805100 | PubMed |
| 8 | 32835356 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/32835356 | PubMed |
| 9 | 37165188 | Profiling the human intestinal environment under physiological conditions. | Nature | 2023 | https://conductscience.org/library/papers/37165188 | PubMed |
| 10 | 37072662 | Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis. | Clin Drug Investig | 2023 | https://conductscience.org/library/papers/37072662 | PubMed |
| 11 | 21487324 | Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. | Pancreas | 2011 | https://conductscience.org/library/papers/21487324 | PubMed |
| 12 | 10071185 | Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. | Hum Genet | 1999 | https://conductscience.org/library/papers/10071185 | PubMed |
| 13 | 22935759 | The determination and interpretation of the therapeutic index in drug development. | Nat Rev Drug Discov | 2012 | https://conductscience.org/library/papers/22935759 | PubMed |
| 14 | 36347964 | Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil. | Br J Cancer | 2023 | https://conductscience.org/library/papers/36347964 | PubMed |
| 15 | 25640272 | Role of ABC transporters in fluoropyrimidine-based chemotherapy response. | Adv Cancer Res | 2015 | https://conductscience.org/library/papers/25640272 | PubMed |
| 16 | 38470044 | Anaerostipes hadrus, a butyrate-producing bacterium capable of metabolizing 5-fluorouracil. | mSphere | 2024 | https://conductscience.org/library/papers/38470044 | PubMed |
| 17 | 38429524 | A gut microbial signature for combination immune checkpoint blockade across cancer types. | Nat Med | 2024 | https://conductscience.org/library/papers/38429524 | PubMed |
| 18 | 32707991 | In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase. | J Clin Med | 2020 | https://conductscience.org/library/papers/32707991 | PubMed |
| 19 | 41853500 | Spatially and temporally precise microbiome profiling in the small intestine using the SIMBA capsule with X-ray tracking. | Front Microbiomes | 2024 | https://conductscience.org/library/papers/41853500 | PubMed |
| 20 | 33944776 | Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. | Elife | 2021 | https://conductscience.org/library/papers/33944776 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42930589 | From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer Outcomes. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42930589 | PubMed |
| 42898560 | Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898560 | PubMed |
| 42872031 | Gut Microbial Metabolism Inactivates Trifluridine and Drives Loss of Anticancer Efficacy. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42872031 | PubMed |
| 42807681 | Gut microbiota-mediated chemotherapy resistance in colorectal cancer: mechanisms and precision interventions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42807681 | PubMed |
| 42375360 | Molecular studies on the impact of microbiome on anticancer drug resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42375360 | PubMed |
| 42147160 | Eggerthella lenta evades bacteriophage through reversible megabase-scale inversions of capsular polysaccharide gene clusters. | Res Sq | 2026 | https://conductscience.org/library/papers/42147160 | PubMed |
| 42079178 | Eggerthella lenta evades bacteriophage through reversible megabase-scale inversions of capsular polysaccharide gene clusters. | bioRxiv | 2026 | https://conductscience.org/library/papers/42079178 | PubMed |
| 41959463 | A widespread gut bacterial lineage distinguished by redox metabolism and phage defense. | bioRxiv | 2026 | https://conductscience.org/library/papers/41959463 | PubMed |
| 41758194 | Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy. | Gut Microbes | 2026 | https://conductscience.org/library/papers/41758194 | PubMed |
| 41595591 | Advances in Understanding the Impact of Human Gut Microbiota on Chemotherapy-Induced Neutropenia. | Biomedicines | 2025 | https://conductscience.org/library/papers/41595591 | PubMed |
| 41497648 | Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent. | bioRxiv | 2025 | https://conductscience.org/library/papers/41497648 | PubMed |
| 41486395 | Harnessing the microbiome for cancer therapy. | Nat Rev Microbiol | 2026 | https://conductscience.org/library/papers/41486395 | PubMed |
| 40824448 | A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity. | Cancer Chemother Pharmacol | 2025 | https://conductscience.org/library/papers/40824448 | PubMed |
| 40391895 | Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. | mBio | 2025 | https://conductscience.org/library/papers/40391895 | PubMed |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| BioProject | PRJNA1169175 |
Source BioProject
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40238917
GET https://conductscience.org/api/papers/v1/40238917/references?page=2